Setmelanotide Acetate
FDA-approved product (solution, subcutaneous), marketed as Imcivree.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- WHO therapeutic group
- Centrally acting antiobesity products
- FDA pharmacologic class
- Melanocortin 4 Receptor Agonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA61.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Setmelanotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia52.9% AI-predicted activityagainst E. coli6 registered studies
- Etrasimod ArginineExisting use: Ulcerative colitis52.8% AI-predicted activityagainst E. coliNo documented evidence found
- PralsetinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 1 more52.8% AI-predicted activityagainst E. coli19 registered studies
- Indinavir SulfateExisting use: HIV infection52.7% AI-predicted activityagainst E. coli50+ registered studies
- ElvitegravirExisting use: HIV infection, HIV-1 infection, Viral disease52.7% AI-predicted activityagainst E. coli50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease52.7% AI-predicted activityagainst E. coliNo documented evidence found
- Metocurine IodideExisting use: Curare alkaloids52.6% AI-predicted activityagainst E. coliNo documented evidence found
- ArgatrobanExisting use: Recurrent thrombophlebitis, Thrombocytopenia, Thrombotic disease52.6% AI-predicted activityagainst E. coli38 registered studies
- AvapritinibExisting use: Cancer, Gastrointestinal stromal tumor, Neoplasm52.6% AI-predicted activityagainst E. coli30 registered studies
- Avatrombopag MaleateExisting use: Hemorrhage, Liver disease, Thrombocytopenia52.5% AI-predicted activityagainst E. coli6 registered studies
- VandetanibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more52.4% AI-predicted activityagainst E. coli50+ registered studies
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.